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glucometer readings during glucose tolerance tests (ivGTT 
or oGTT), insulin tolerance test (ITT), graded glucose infu-
sion (GGI) and clamp.
Conclusion Our data demonstrate that the real-time 
telemetry method is reliable for monitoring blood glucose 
remotely and continuously in conscious, stress-free, and 
moving-free NHPs with the advantages highly valuable to 
diabetes research and drug discovery.
Keywords Diabetes · Nonhuman primate · Continuous 
glucose monitoring · Implantable telemetry device · 
Glucose circadian
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Introduction
Chronically dysfunctional carbohydrate metabolism 
results in diabetes due to a relative deficiency of insulin. 
Various animal models have been used in research for 
understanding diabetes and discovering novel therapies 
for the disease [1–4]. Nonhuman primates (NHPs) can 
naturally develop to Type 2 diabetes mellitus (T2DM) 
Abstract 
Aims Continuous blood glucose monitoring, especially 
long-term and remote, in diabetic patients orresearch is 
very challenging. Nonhuman primate (NHP) is an excel-
lent model for metabolic research,because NHPs can natu-
rally develop Type 2 diabetes mellitus (T2DM) similarly 
to humans. This study was to investigate blood glucose 
changes in conscious, moving-free cynomolgus monkeys 
(Macaca fascicularis) during circadian, meal, stress and 
drug exposure.
Materials and methods Blood glucose, body temperature 
and physical activities were continuously and simultane-
ously recorded by implanted HD-XG telemetry device for 
up to 10 weeks.
Results and discussion Blood glucose circadian changes 
in normoglycemic monkeys significantly differed from that 
in diabetic animals. Postprandial glucose increase was more 
obvious after afternoon feeding. Moving a monkey from its 
housing cage to monkey chair increased blood glucose by 
30% in both normoglycemic and diabetic monkeys. Such 
increase in blood glucose declined to the pre-procedure 
level in 30 min in normoglycemic animals and >2 h in dia-
betic monkeys. Oral gavage procedure alone caused hyper-
glycemia in both normoglycemic and diabetic monkeys. 
Intravenous injection with the stress hormones, angiotensin 
II (2 μg/kg) or norepinephrine (0.4 μg/kg), also increased 
blood glucose level by 30%. The glucose levels measured 
by the telemetry system correlated significantly well with 
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in a way similar to the progression and onset of T2DM 
in humans. Dysmetabolic NHPs have thus been used for 
diabetes and obesity research in many studies [5–8]. NHP 
models also play an important role in screening novel 
compounds for regulation of food intake, blood glucose, 
and/or body weight. The data from NHP models can 
result in discovery and validation of new mechanism or 
therapeutic strategy and target of dysmetabolic diseases 
[9, 10].
Using implanted telemetry device for continuous glu-
cose monitoring has been very limited in biomedical 
research, especially in large animals. The conventional 
ways, such as handheld glucometer, clinical chemis-
try analyzer, or analox analyzer, are generally used for 
blood glucose measurement. These conventional meth-
ods require sampling blood periodically. Bleeding may 
induce stress and blood volume decline obviously in 
small animals if bleeding frequently. Periodical sam-
pling may possibly miss some critical data points during 
sampling intervals. Thus, ‘around the clock’ real-time 
measurements of blood glucose in unstressed, moving-
free animals have some unique advantages in pre-clini-
cal research. In addition, sensing glucose from the blood 
directly has the potential to reduce or eliminate many 
issues commonly encountered with interstitial glucose 
sensing [11]. The HD-XG implantable glucose device 
(Data Sciences International, Saint Paul, MN, USA) 
provides continuous measurement of blood glucose, 
temperature, and locomotor activity for up to 2  months 
in rodents [12]. This study investigated the real-time 
changes of blood glucose during circadian, meal, stress 
procedures, and drug exposures by the modified HD-XG 
transmitter device in conscious, moving-free cynomolgus 
monkeys (Macaca fascicularis) with or without diabe-
tes. An electrochemical glucose oxidase sensor placed in 
one of the monkey femoral arteries provided continuous 
real-time measurements of blood glucose. A tempera-
ture sensor contained in the implanted transmitter body 
provided continuous real-time temperature information. 
Signal strength variation due to physical activity of the 
subject provided a continuous real-time activity count 
as calculated in the DEM/MX2 (Data Sciences Interna-
tional, Saint Paul, MN, USA).
Methods
Animals and animal care
Experiments were performed in cynomolgus monkeys 
of either sex (Table  1). These monkeys were individually 
housed and maintained in our animal facility in accord-
ance with the guidelines approved by the Association for 
Assessment and Accreditation of Laboratory Animal Care 
(AAALAC). The room temperature was maintained at 
~21 °C with a 12-h light/dark cycle with lights off from 
7 pm to 7 am. All the animals had access ad libitum to water 
and a complete, nutritionally balanced normal diet (Beijing 
Keao Xieli Feed Co., LTD, Beijing, China) enriched with 
seasonal fruit and vegetables. The experimental protocol 
was approved by the Institutional Animal Care and Use 
Committee (IACUC) of Crown Bioscience, Inc.
Implantation of HD-XG telemetry device
An implantable telemetry device (HD-XG, DSI, St. Paul, 
MN, USA) consists of one glucose sensor lead, one refer-
ence lead and device body (Fig. 1a) and is packed and steri-
lized ready for use. The operation room and surgical tools 
were disinfected 1  day before surgical operation. On the 
experimental day for device implantation, each overnight-
fasted monkey received ketamine (15 mg/kg, Fujian Gutian 
Pharmaceutical Co. Ltd., Fujian, China) and 0.01  mg/kg 
buprenorphine by intramuscular administration with addi-
tional ketamine (5  mg/kg) as needed during operation. 
Body temperature was monitored and maintained at ~37 °C 
by a thermostatically controlled warm water-circulating 
pad placed beneath the body. The skin around the intended 
incision site was shaved and made aseptic with betadine 
starting from the center of the incision region and spiral-
ing outward. Then, the area was swept with a 70% ethanol 
gauze pad. The vital signs, such as heart rate, blood pres-
sure, blood oxygen saturation, and respiration rate, were 
Table 1  Characteristics of the 
cynomolgus monkeys enrolled 
in the experiment









Normoglycemia A07 5 4.7 58 5.3 4.3
L02 8 6.1 53 49.6 5.5
V01 9 7.8 63 29.9 4.4
Diabetes B02 17 5.9 120 9.6 4.7
J04 16 7.1 114 30.3 5.9
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monitored during surgery. A small incision was made in the 
femoral area and one branch from the femoral artery was 
carefully dissected. The glucose sensor electrode of one 
HD-XG device was cannulated into the artery branch, and 
its tip reached the main femoral artery with ligation and 
fixation of the artery branch together with the sensor elec-
trode. The reference electrode and device body were fixed 
subcutaneously in the place near by the femoral artery. The 
incision was then sutured and covered properly with gauze. 
The monkey was placed in a monkey jacket with an inter-
mediate transmitter placed in jacket pocket (Fig. 1b, c). The 
monkey was returned to its housing cage after regaining 
consciousness. Buprenorphine at 0.01 mg/kg was injected 
intramuscularly every 6–12 h after implantation for 2 days 
and antibiotic amoxicillin at 7 mg/kg was also given intra-
muscularly if needed. The health of a surgical animal was 
closely monitored during 1 week recovery. Food and water 
were provided again after the surgical animal was returned 
to its housing cage and fully recovered from anesthesia.
Device calibration
Fibrin and/or tissue adhered to the glucose sensor area of 
the electrode placed in the artery can affect glucose read-
ings. To obtain an optimal performance and accuracy of 
glucose readings, the implanted HD-XG device must be 
calibrated by reference measurements of tail vein blood 
samples with the Nova StatStrip Glucose Meter  (Nova® 
Biomedical, Waltham, MA, USA) from time to time dur-
ing study. Raw telemetry data are recorded in nanoamperes 
(nA) and calibration reference values are recorded in mg/
dL. The calibration algorithm converts the telemetry (nA) 
data to the values that are equivalent to the appropriate mg/
dL results.
Multi‑point calibration
Multi-point calibrations were needed to establish a linear 
relationship between the sensor outputs and blood glucose 
levels at the beginning of initial data collection and also at 
the end of the study. During calibration, the blood glucose 
levels should differ by at least 100 mg/dL to minimize cali-
bration errors due to the inaccuracy of glucose reference. 
Our study used intravenous injection of glucose to get 
multi-point calibrations.
Single‑point calibration
Single-point calibrations were performed to prevent non-
physiologic changes in the baseline glucose value over time 
during the study. Non-physiologic changes include enzyme 
instability due to sensor drifting or fibrin and tissue growth 
on the sensor electrode. Single-point calibrations were per-
formed at least twice per week at the same time of day and 
during a time period when the animal’s blood glucose was 
relatively stable.
Fig. 1  a Implantable HD-XG 
telemetry device for continuous 
monitoring of glucose, tempera-
ture, and locomotor activity. b 
Experimental monkey with an 
implantable device and wearing 
a monkey jacket in which a 
small transmitter was placed 
and used for signal collection 
from outside cage. c Signals of 
blood glucose, body tem-
perature, and locomotor activity 
from a conscious, moving-free 
monkey were recorded continu-
ously from its outside cage. d 
Significant correlation between 
the blood glucose levels meas-
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Data collection
An implanted HD-XG glucose electrode continuously 
sensed the blood glucose and recorded the electrical sig-
nals during a study. After calibration with the glucose 
levels measured by the Nova StatStrip Glucose Meter 
 (Nova® Biomedical, Waltham, MA, USA), the recorded 
electrical signals were converted to glucose concentra-
tions. In the meantime, blood glucose concentrations 
during various glucose tests or drug challenges were also 
measured by the Nova StatStrip Glucose Meter to further 
validate telemetry data if needed.
To test insulin resistance and β-cell insulin secretory 
response to acute hyperglycemia, intravenous glucose 
tolerance test (ivGTT) was conducted. The experimental 
animals were fasted overnight (around 16  h) and anes-
thetized with ketamine at 10  mg/kg (i.m.) initially plus 
additional dose (5  mg/kg, i.m.) during the procedure if 
needed. When blood glucose stabilized for approximately 
30  min via observation of HD-XG glucose signals, the 
glucose solution (0.25 g/kg = 0.5 mL/kg of 50% dextrose) 
was intravenously infused via one cephalic vein within 
30 s, and then the system was flushed with 5 mL heparin-
ized saline to push in the residual glucose.
Hyperinsulinemic-euglycemic clamp was also tested 
in this study. The animals were fasted overnight (around 
16 h) and anesthetized with ketamine at the initial dose of 
10 mg/kg (i.m.) plus additional 5 mg/kg each time during 
the procedure if needed. In the period of narcosis, vital 
signs were monitored. The cephalic or saphenous veins 
were cannulated for glucose and insulin infusions. Insulin 
(biosynthetic human insulin, Novo Nordisk, Denmark) 
was diluted to 300 mIU/mL by isotonic saline to which 2 
mL of the subject’s blood per 50 mL was added in order 
to avoid adhesion of insulin to the syringe plastic surface. 
After blood glucose stabilized for 30  min via observa-
tion of the HD-XG glucose signals, insulin infusion at 
various rates was given during the first 5 min to quickly 
adjust blood glucose near the targeted level (70 ± 5  mg/
dL). However, diabetic monkeys needed 20–30  min for 
the adjustment. The infusion rate for the hyperinsuline-
mic-euglycemic clamp was then maintained at 40 mU/
m2 surface area × min as reported previously [5, 13, 14]. 
A variable amount of 20% d-glucose was intravenously 
infused to maintain the blood glucose level. The initial 
glucose infusion rate (GIR) was at 5 or 6 mg/kg/min for 
normal monkeys and 2 mg/kg/min for diabetic monkeys, 
and then the infusion rate was adjusted until reaching a 
stable glucose level around 75 mg/dL for 30 min. During 
the weaning period, insulin infusion was terminated and 
blood glucose was continuously monitored with glucose 
infusion if needed until blood glucose was above 40 mg/
dL and stable.
Results
Validation of the blood glucose levels measured 
by an implanted HD-XG device
To validate the reliability of the telemetry method, blood 
glucose levels were measured at different time points and 
with or without various challenges 1  week after device 
implantation. During the study, 187 blood glucose param-
eters were collected by both telemetry and glucometer 
methods in normoglycemic (n = 3) and diabetic (n = 2) 
monkeys. The blood glucose levels measured by the telem-
etry method were highly correlated with those read by the 
glucometer (Fig.  1d, Y = 0.9804x + 3.2753, R² = 0.9466, 
p < 0.001), which suggests that the telemetry method with 
the implantable HD-XG device is reliable for continuous 
blood glucose monitoring.
Blood glucose fluctuations during daily activities
With the clinical handheld glucometer method, continu-
ously monitoring blood glucose day and night for a long 
term is impossible in conscious, stress-free, and freely 
moving monkeys. Figure 2 shows the circadian oscillations 
of blood glucose levels in a normoglycemic monkey for 
3 days accompanied with the data from its physical activity 
and body temperature (Fig. 2). Such monitoring could last 
up to 10  weeks after one sensor was successfully placed 
in a femoral artery, and the HD-XG device body was 
implanted into one subcutaneous space. Interestingly, the 
pattern of blood glucose circadian in the normoglycemic 
monkeys (n = 3) differed from the one observed from the 
diabetes monkeys (n = 2). The averaged blood glucose level 
in the normoglycemic animals decreased gradually from 3 
am to a low level within 2 h and then stayed at the low level 
until afternoon feeding at 3 pm (Fig. 3). However, the aver-
aged blood glucose level in the diabetic animals increased 
gradually around 7 am to a new high level and then main-
tained at the relatively high level until late evening after 
9 pm (Fig.  3). Both normoglycemic (n = 3) and diabetic 
(n = 2) animals enrolled in this study did not show obvious 
postprandial hyperglycemia after morning feeding, but the 
blood glucose level increased by 20 to 30% after afternoon 
feeding (Fig. 4a).
Blood glucose response to experimental procedure 
or drug challenge
To examine if an experimental procedure could cause stress 
and alter blood glucose level, an overnight-fasted monkey 
was moved out of its cage by grabbing his neck collar to 
let him sit in a monkey chair. This procedure increased the 
blood glucose level approximately 30 mg/dL, which lasted 
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Fig. 2  Representative traces collected continuously from a conscious 
monkey implanted with a HD-XG device. From top to bottom, body 
temperature (1st trace) with the maker on top to indicate day (open 
bar) and night (black bar) time, physical activity (2nd trace), blood 
glucose electrical signal (3rd trace), blood glucose level (4th trace) 
after calculation from the corresponding glucose electrical signal
Fig. 3  Daily blood glucose 
fluctuations averaged from 
7-day consecutive recordings of 
each monkey in normal (n = 3, 
upper panel) and diabetic (n = 2, 
low panel) NHPs. The solid line 
in each panel represented the 
median level of instant blood 
glucose concentration from the 
seven consecutive days of each 
monkey for normoglycemia 
(n = 3) and diabetes (n = 2) 
ones, and the shadowed areas 
above or below the line were 
the deviations of high and low 
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about 10–20 min (Figs. 4b, 5a) in normoglycemic monkeys 
(n = 3). However, the same procedure increased blood glu-
cose level by 50–70 mg/dL in the diabetic animals (n = 2), 
which lasted over 2 h (Figs. 3, 5a).
Oral or nasal gavage is a conventional procedure fre-
quently used for drug dosing in NHPs. To test if such pro-
cedure could also cause stress and alter blood glucose lev-
els, an overnight-fasted monkey placed in a monkey chair 
underwent a sham oral gavage procedure (placing a gavage 
tube into the stomach without giving food, drug, or solu-
tion). The procedure alone caused the increase in blood glu-
cose levels by 30–50% in both normoglycemia and diabetes 
monkeys (Figs.  4b, 5b). However, the procedure-induced 
hyperglycemia lasted much longer in diabetes (>60  min, 
n = 2) than in normoglycemia (about 20  min, n = 3) mon-
keys (Figs. 4b, 5b).
Stress-induced hyperglycemia during chairing or gav-
age procedure most likely resulted from neuronal alert and 
hormonal secretion. To test if stress hormone could cause 
hyperglycemia, norepinephrine and angiotensin II were 
administered intravenously to the monkeys with implanted 
HD-XG devices. The animals with norepinephrine chal-
lenge were fasted overnight (around 16  h) and anesthe-
tized with ketamine 10 mg/kg (i.m.) initially and additional 
5  mg/kg if needed during the procedure. After the blood 
glucose level was stable for 30 min, norepinephrine solu-
tion at 0.4 μg/kg/min was infused intravenously for 40 min. 
Blood glucose gradually increased and reached the peak 
near the end of infusion in both normoglycemic (L02) 
and diabetic (J04) monkeys (Fig.  6a). The hyperglycemic 
response to norepinephrine slowly subsided after cessation 
of intravenous norepinephrine infusion. Interestingly, the 
blood glucose level was lower at the end of infusion than 






































Day time B  
Fig. 4  a Typical effects of feeding on blood glucose were shown 
from one conscious normoglycemia monkey. The solid line was the 
median level of instant blood glucose averaged from the seven con-
secutive days, and shadowed areas above or below the line were the 
deviations of high and low levels of blood glucose. b Representative 
stress responses to the operation procedures in one conscious nor-
moglycemia monkey implanted with the telemetry device. Procedure 
from cage to chair, the monkey was removed from its cage and placed 
into a monkey chair. Gavage procedure, the monkey was chaired and 

































Procedure from cage to chair 
A  B  
Fig. 5  Effects of operation procedures on blood glucose in normo-
glycemia (n = 3) and diabetes (n = 2) monkeys with implanted telem-
etry device. Procedure from cage to chair (a), the monkeys were 
removed from their cages and placed into their monkey chairs. Gav-
age procedure (b), the monkeys were chaired and encountered oral 
gavage operation without delivery of any drug or solution. Compared 
with normoglycemic monkeys, the stress responses to the operation 
procedures were markedly prolonged in diabetes animals
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The overnight-fasted monkeys were restrained in the 
monkey chair. After stabilization of their blood glucose 
levels based on the HD-XG glucose signals, angiotensin 
II at 2  μg/kg was administered intravenously by bolus 
injection. Blood glucose level gradually increased and 
reached the peak within 10 min after angiotensin II injec-
tion in both normoglycemic (L02) and diabetic (J04) 
monkeys (Fig. 6b). The hyperglycemic response to angio-
tensin II slowly waned and lately even went lower than 
the pre-angiotensin II level in the diabetic animal (J04, 
Fig.  6b). It is interesting that intravenous bolus injec-
tion of acetylcholine at 1  μg/kg did not alter blood glu-
cose levels in both normoglycemic and diabetic mon-
keys implanted with HD-XG telemetry devices (data not 
shown).
Glucose tolerance test and other tests in NHPs 
with implanted HD-XG device
To evaluate β-cell function, ivGTT, oGTT, ITT, GGI, and 
glucose clamp were performed in the experimental mon-
keys according to the method reported previously [5, 6, 
14–17]. The results obtained from implanted HD-XG 
telemetry device were compared with those measured by 
the glucometer (StatStrip Xpress meter, Waltham, MA, 
USA) via the tail prick method.
ivGTT
After intravenous glucose injection blood glucose 
































Fig. 6  Effects of norepinephrine and angiotensin II on blood glucose 
in normoglycemic and diabetic monkeys implanted with the telemetry 
device. Left panel norepinephrine at 0.4 µg/kg/min was intravenously 
infused for 40 min in anesthetized (10 mg/kg ketamine, intramuscu-
larly) normoglycemic (L02) and diabetic (J04) monkeys. The blue 
bar represents the time period with norepinephrine infusion. Right 
panel angiotensin II at 2  µg/kg was intravenously injected in con-
scious normoglycemic (L02) and diabetic (J04) monkeys. The arrows 
indicated the time point for angiotensin II bolus injection. L02 and 
J04 were the identification codes of the normoglycemic and diabetic 
monkeys used in both left and right panels
Fig. 7  Representative data to 
make comparison of the out-
comes measured by glucometer 
and telemetry. Blood glucose 
levels responded to single 
ivGTT in one normoglycemic 
animal (upper left) and dual 
ivGTTs in one normoglycemic 
(Blue) and one diabetes (Green) 
monkeys (upper right) meas-
ured with both telemetry (solid 
line) or glucometer (scatted 
squares or circles). Blood glu-
cose levels responded to single 
oGTT (low left) and ITT (low 
right) in one normoglycemic 
monkey were measured with 
both the telemetry (solid line) 
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telemetry device (Fig. 7, upper panels). Also, blood glu-
cose levels were measured by the glucometer (StatStrip 
Xpress meter) via the tail prick method immediately 
before and at 3, 5, 7, 10, 15, 20, and 30  min after glu-
cose infusion for single ivGTT (Fig. 7, IVGTT) or longer 
according to the observation from HD-XG glucose sig-
nals for dual ivGTTs (Fig.  7, Dual IVGTT). The results 
showed that the glucose levels measured by telemetry 
matched well to the readings by glucometer.
oGTT
The experimental animals (normoglycemia, n = 3 and 
diabetes, n = 2) were fasted overnight (approximately 
16  h) and restrained in the monkey chair. When blood 
glucose stabilized for around 30  min via observation of 
the HD-XG glucose signals, the glucose solution (1.75 g/
kg = 5  mL/kg of 35% dextrose) was given to the animal 
via oral gavage. Blood glucose was measured by glucom-
eter (StatStrip Xpress meter) immediately before and at 
15, 30, 60, 90, 120, and 180 min after glucose adminis-
tration. Meanwhile, blood glucose levels were monitored 
by the implanted HD-XG device throughout the entire 
test. The results were plotted and correlated with each 
other very well (Fig. 7, OGTT).
ITT
ITT is used to examine if the body produces enough 
ACTH (adreno-cortico-trophic hormone) and growth hor-
mone under stress. The ‘stress’ in this test was to lower 
blood sugar (hypoglycemia) by injected insulin under 
very controlled conditions. ACTH stimulates the adre-
nal glands to make cortisol which is a steroid hormone 
and has many functions, including balancing the effect of 
insulin in regulating blood glucose levels. Five animals 
(normoglycemia, n = 3 and diabetes, n = 2) were fasted 
overnight (16  h) and restrained in the monkey chair. 
When blood glucose levels stabilized for around 30 min 
via observation of the HD-XG glucose signals, the insu-
lin solution (0.15 U/kg = 0.15 mL/kg of insulin injection) 
was given to each animal via S.C. injection [5]. Blood 
glucose levels were measured by the glucometer method 
(StatStrip Xpress meter) immediately before and at 30, 
60, 90, and 120 min after insulin administration (Fig. 7, 
ITT). Meanwhile, blood glucose levels were monitored 
and recorded by implanted HD-XG devices. The results 
were plotted against the time and were correlated very 
well between the telemetry results and the glucometer 
readings.
GGI
The animals were fasted overnight (around 16 h) and anes-
thetized with an initial dose of ketamine at 10 mg/kg (i.m.) 
plus additional dose at 5 mg/kg each time during the pro-
cedure if needed. Then, an intravenous catheter was placed 
in one cephalic or saphenous vein. After blood glucose sta-
bilized for 30 min via observation of the HD-XG glucose 
signals, glucose (20% dextrose) was continuously infused 
via the cannulated vein for 40 min per stage with the initial 
2 mg/kg/min and then the dose was doubled at each succes-
sive stage up to 16 mg/kg/min by four stages (Fig. 8, low 
panel). Blood glucose was monitored and recorded by the 
implanted telemetry device and also measured by the glu-
cometer (StatStrip Xpress meter) with the tail prick method 
at the time points immediately before and 40, 80, 120, and 
160  min after glucose infusion. The blood glucose levels 
measured by the telemetry system matched well with those 
tested by the glucometer method (Fig. 8).
Hyperinsulinemic‑euglycemic clamp
The blood glucose levels measured by the HD-XG telem-
etry method matched the glucometer readings well (Fig. 9). 
Such match was observed with the glucose levels not only 
above 100  mg/dL or even above 150  mg/dL (Fig.  9, ani-
mal B02 and J04), but also low approximately 50  mg/dL 
(Fig.  9, animal A07, V01, L02). These results indicate 
that HD-XG telemetry technology can be used for glucose 








































Fig. 8  Comparison of the outcomes measured by glucometer and 
telemetry. Graded glucose infusion in anesthetized normoglyce-
mic (blue line, n = 1) and diabetic (green and red lines, one animal 
per line) monkeys with similar glucose levels measured by telem-
etry (solid line) and glucometer (solid dotted circles). Each animal 
was anesthetized with ketamine at 10  mg/kg (i.m.) plus additional 
dose 5 mg/kg each time during procedure if needed. The upper panel 
shows the glucose levels and low panel shows the graded glucose 
infusion rates
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Discussion
This is the first successful demonstration of telemetry mon-
itoring of blood glucose continuously in NHPs. Our data 
show that blood glucose in conscious, non-stressed cyn-
omolgus monkeys can be accurately measured and recorded 
by the implanted HD-XG glucose sensor and its data col-
lection system. The method can monitor and record instant 
blood glucose level, body temperature, and animal activity 
continuously for up to 10 weeks. The blood glucose param-
eters collected by the telemetry method correlated signifi-
cantly well with the readings tested by the classical glu-
cometer method at different glucose levels (Fig. 1d), even 
under various challenges (Figs. 7, 8, 9). The advantages of 
glucose monitoring by the implantable telemetry device in 
NHPs include: (1) long-term monitoring; (2) 24 hr consec-
utive data collection to observe circadian and postprandial 
glucose changes; (3) no bleeding during measurement; (4) 
no restriction even in fully conscious, free-moving animals; 
(5) no anesthesia even for ivGTT or glucose clamp; (6) no 
stress as each animal with implanted device moves freely; 
(7) less labor intensive procedure during ivGTT, oGTT, 
ITT or clamp; and (8) instant glucose readings without 
blood test. Our study demonstrates that remotely and con-
tinuously monitoring blood glucose via implanted HD-XG 
telemetry device in conscious, stress-free, and freely 
moving monkeys is feasible and provides a sophisticated 
approach to investigate glucose changes due to daily activi-
ties, neuronal and hormonal changes, or physical/chemi-
cal challenges. In fact, moving a monkey from its cage to 
the monkey chair or proceeding an oral gavage induced 
hyperglycemia in both normoglycemia or diabetes monkeys 
(Fig. 5). Such stress-induced hyperglycemia could be simu-
lated with intravenous administration of stress hormones 
(Fig. 6). If glucose tests with glucometer or blood sampling 
are infrequent, such procedure-induced hyperglycemia in 
conscious animals could be missed or be misinterpreted as 
a baseline or treatment effect. Therefore, continuous moni-
toring of blood glucose by the implantable telemetry device 
could avoid not only some unnecessary stressful procedures 
but also some misinterpretation of data.
It is interesting that compared with nighttime, blood 
glucose was relatively lower during most daytime in the 
normoglycemic monkeys, but not the case in the diabetic 
ones (Fig. 3). The daily circadian of blood glucose in the 
diabetes monkeys was higher during daytime with starting 
from very early morning (Fig. 3). This phenomenon could 
result from insulin resistance and relative insulin deficiency 
in diabetic NHPs, which is similar to the observation in 
diabetic patients [18]. Clinically, glucose circadian changes 
are influenced by levels of both insulin and the counter-
regulatory hormones, such as glucagon, adrenaline, growth 
hormone, and cortisol. There is a surge in the amount of 
released growth hormone beginning from the middle night, 
followed by a surge in cortisol to increase liver blood glu-
cose production. These processes are offset by increased 
insulin secretion to maintain blood glucose relatively sta-
ble in normoglycemic individuals. However, in diabetic 
patients, hormone changes during sleep can have a power-
ful effect on morning blood glucose level, an event dubbed 
the “dawn phenomenon” [19, 20].
Our data clearly showed that physical activity and body 
temperature gradually declined from 7 pm each day (Fig. 2). 
Then, physical activity and body temperature changes 
began to increase from very early morning (Fig. 2). Under 
normal physiological condition, our body would enhance 
glucose generation and usage according to hormone secre-
tion, physical activity, and energy needs. It is well recog-
nized that the main cause of T2DM is a combination of 
varying degrees of insulin resistance and relative insulin 
deficiency [21–23]. Due to insulin resistance and impaired 
glucose handling (Fig.  5), stress or experimental proce-
dure resulted in hyperglycemia which took much longer 
time to decline to the pre-level in diabetic monkeys than 
in normoglycemic ones (Fig.  5). Therefore, the increased 
activities from early morning to later in the day resulted 
in the increase in blood glucose and less physical activ-
ity after 7  pm led to gradual decrease in blood glucose in 
diabetes NHPs due to their impaired glucose handling 
(Fig. 3). However, the daily circadian of blood glucose in 
the normoglycemic NHPs was opposite to that in diabetes 
animals (Fig. 2). The increase in physical activity resulted 
in low blood glucose during early morning and most of 
other daytimes, except the time after afternoon feeding. 
Less physical activity after 7 pm showed resulted in higher 
blood glucose until early morning (Figs. 2, 3). The poten-



















GIR: Glucose infusion 
rate (mg/kg/min)
GIR A07 = 8 
GIR V01 = 8
GIR L02 = 11
GIR B02 = 2
GIR J04 = 5
Fig. 9  Comparison of the blood glucose levels measured by glucom-
eter (scatted dots) and telemetry (solid lines) during glucose clamp. 
Hyperinsulinemic-euglycemic clamps were conducted in normo-
glycemic (n = 3) and diabetic (n = 2) monkeys. Blood glucose was 
measured by both telemetry (solid line) and glucometer (solid scat‑
ted circles) methods. The animals were anesthetized with ketamine at 
10  mg/kg (i.m.) initially and then 5  mg/kg each time during clamp 
procedure if needed
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better in normoglycemic monkeys than in diabetic ones [5]. 
As physical activity enhances insulin secretion and sen-
sitivity in normoglycemic animals [24, 25], the body can 
regulate more glucose per unit time and decreased blood 
glucose during physical activity. Therefore, the pattern of 
glucose circadian in diabetic monkeys differs from that in 
normoglycemic NHPs. This novel finding results from con-
tinuous glucose monitoring by the implantable telemetry 
method which provides the instant blood glucose concen-
tration 24 h per day for up to 10 weeks (Figs. 2, 3). It would 
be very difficult to find such circadian difference between 
normoglycemia and diabetes in NHPs if the classical glu-
cometer method was used for periodical determination of 
blood glucose, especially during night. Also, the glucom-
eter method would obviously disturb the monkey’s normal 
activity cycle a lot which may obscure the true pattern of 
blood glucose fluctuation if frequent measurements are 
made.
The monkeys housed in our animal facility were fed 
twice per day. The postprandial increase in blood glucose 
was very minor with a few small fluctuations after morn-
ing feeding and was more obvious with one main peak 
after afternoon feeding (Fig.  4a). This pattern of food 
intake in NHPs differs from humans. Generally speaking, 
humans complete their meals in a certain period of time 
(most likely less than 1 h). Blood glucose increase after a 
meal is more obvious and relatively predictable in humans. 
However, most of our housed monkeys might not com-
plete their meals in a relatively short period of time, espe-
cially after morning feeding. The monkeys could eat and 
play with their food for quite a while, which initiated those 
small fluctuations of blood glucose after morning feed-
ing (Fig.  4a). Postprandial increase in blood glucose was 
more obvious with one main peak after afternoon feeding. 
This peak potentially indicated the change of the housed 
monkey behavior. They were smart to intake enough food 
before 7  pm as the access became difficult after light off. 
This postprandial blood glucose pattern in housed NHPs 
also resulted from the advantage of the implantable telem-
etry device which did not affect animal normal behavior.
Clinically, the FDA-approved Continuous Glucose Mon-
itoring (CGM) system (Dexcom G4 PLATINUM Continu-
ous Glucose Monitoring System, Dexcom, Inc., San Diego, 
CA, USA) can sense interstitial glucose frequently in dia-
betic patients to inform exogenous insulin delivery timing 
and dosage. Compared with the arterial glucose telemetry 
monitoring method used in this study, the advantages of the 
clinical CGM system (subcutaneously) are relatively easier 
installation, less expensive, less invasive, and more accept-
able safety profile which becomes the mainstay for patient 
use. For animal research, the disadvantages of the clinic 
CGM system can firstly manifest moderately delayed glu-
cose readings (5–12 min) [26–29] and likely worsen with 
implantation time as encapsulation develops [30, 31]. Sec-
ondly, the CGM system readings of glucose level can vary 
due to local fluctuations of subcutaneous blood flow by the 
change of temperature and/or mechanical pressure [32, 33]. 
Thirdly, subcutaneously inflammatory response results in 
biofouling and encapsulation, which limits sensor service 
time (less than 2 weeks) [26, 34]. Fourthly, fixation of sub-
cutaneously inserted sensor for stable data collection in 
physically active monkeys is very challenging. To stabilize 
implanted sensor and to avoid any delay of glucose read-
ing, this study used the implanted HD-XG telemetry device 
to access arterial vasculature and provided real-time blood 
glucose information [12].
In summary, the HD-XG telemetry method was success-
fully used to continuously monitor and record real-time 
blood glucose for the first time in conscious, freely mov-
ing NHPs. This novel technology allows researchers to dis-
cover blood glucose circadian and changes due to physical 
activities or natural behaviors, such as eating and sleep-
ing, as well as stress or drug challenges. By this telemetry 
approach, we can now continuously collect blood glucose 
data for up to 10 weeks without blood sampling which can 
cause animal stress and test variability commonly associ-
ated with classical glucose assays (glucometer or lab blood 
test). Therefore, using such telemetry technology can help 
us to further understand glucose metabolism under more 
natural physiologic condition.
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